7 recruiting, 3 not yet recruiting, 2 completed, 1 active not recruiting. 8 Phase 1, 7 Phase 2, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Recruiting 4, Not yet recruiting 2, Completed 1, Terminated 1 |
| Phase 2 | 7 | Recruiting 4, Active not recruiting 1, Not yet recruiting 1, Terminated 1 |
| Early Phase 1 | 1 | Withdrawn 1 |
Follow Clear Cell Renal Cell Carcinoma (ccRCC): new trials by email Literature Review of Clear Cell Renal Cell Carcinoma (ccRCC) trials Research Report on Clear Cell Renal Cell Carcinoma (ccRCC)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC) BMS-986527, Nivolumab, Cabozantinib - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | 112 | 2026-12-31 | 2026-09-30 |
| CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC 89Zr-Girentuximab - Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 10 | 2026-09-16 | 2026-07-21 |
| Evaluation of Safety, Pharmacokinetics, Distribution，Radiation Safety and Sensitivity/Specificity of PET/CT Imaging With 68Ga-NYM096 in Participants With IRM 68Ga-NYM096 injection - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Not yet recruiting | Norroy Bioscience Co., LTD | 20 | 2026-09-01 | 2026-08-17 |
| REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma REGN15505, REGN15505+Cemiplimab, REGN15505+REGN4336 - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 265 | 2026-07-20 | 2026-09-28 |
| A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC) Fianlimab, Ipilimumab, Nivolumab - Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC) | Phase 2 | Recruiting | Brian Rini | 120 | 2026-04-29 | 2026-09-04 |
| KSD-201 Treatment for Advanced Clear Cell Renal Cell Carcinoma: an Early Exploratory Clinical Study KSD-201 - Clear Cell Renal Cell Carcinoma (ccRCC) | Early Phase 1 | Withdrawn | Kousai Bio Co., Ltd. | 2026-03-01 | 2026-05-08 | |
| Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC Pucotenlimab combination with Vorolanib - Vorolanib, Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Recruiting | Sun Yat-sen University | 21 | 2025-07-10 | 2026-02-04 |
| A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoCAIX in Patients With CAIX-positive Cancer [68Ga]Ga-OncoCAIX - Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 | Completed | Philogen S.p.A. | 20 | 2025-04-16 | 2026-01-13 |
| Multicenter Study of 18F-Labeled NY104 for PET/CT Imaging in Renal Cell Carcinoma 18F-NY104 PET/CT - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Recruiting | The Affiliated Hospital of Qingdao University | 120 | 2025-04-12 | 2026-09-17 | |
| Evaluation of HPGD and SCLO2A1 Expression in Clear Cell Renal Cell Carcinoma Patients Immunohistochemistry; WB; PCR - Clear Cell Renal Cell Carcinoma (ccRCC) | Completed | Shang Panfeng | 40 | 2024-07-01 | 2025-01-16 | |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors Darlifarnib, Cabozantinib, Adagrasib - Solid Tumors With HRAS Alterations, Non Small Cell Lung Cancer (NSCLC) | Phase 1 | Recruiting | Kura Oncology, Inc. | 300 | 2023-10-18 | 2026-10-14 |
| Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors Zanzalintinib, Nivolumab, Ipilimumab - Renal Cell Carcinoma (RCC), Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 1 | Recruiting | Exelixis | 1394 | 2021-12-14 | 2026-10-01 |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors REGN5678, Cemiplimab - Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 345 | 2019-08-12 | 2026-07-09 |
| A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003) Belzutifan, Cabozantinib - Renal Cell Carcinoma (RCC), Clear Cell Renal Cell Carcinoma (ccRCC) | Phase 2 | Active not recruiting | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 118 | 2018-09-27 | 2024-12-20 |
| Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC) CB-839, Nivolumab - Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma | Phase 1 / Phase 2 | Terminated | Calithera Biosciences, Inc | 118 | 2016-08-01 | 2023-03-17 |
Carcinoma, Renal Cell (15) · Carcinoma, Non-Small-Cell Lung (3) · Kidney Neoplasms (3) · Colorectal Neoplasms (2) · Carcinogenesis (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Transitional Cell (1) · Melanoma (1) · Recurrence (1) · Squamous Cell Carcinoma of Head and Neck (1)
Adenocarcinoma (15) · Carcinoma (15) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Kidney Diseases (15) · Male Urogenital Diseases (15) · Neoplasms (15) · Neoplasms by Histologic Type (15) · Neoplasms by Site (15) · Neoplasms, Glandular and Epithelial (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15) · Urologic Diseases (15) · Urologic Neoplasms (15) · Kidney Neoplasms (12)
Nivolumab (4) · cabozantinib (3) · cemiplimab (3) · Ipilimumab (2) · CB-839 (1) · Docetaxel (1) · Immunohistochemistry (1) · Prednisone (1) · adagrasib (1) · belzutifan (1) · relatlimab (1) · vorolanib (1)
Regeneron Pharmaceuticals (2) · Brian Rini (1) · Calithera Biosciences, Inc (1) · Exelixis (1) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company (1) · Kousai Bio Co., Ltd. (1) · Kura Oncology, Inc. (1) · Massachusetts General Hospital (1) · Norroy Bioscience Co., LTD (1) · Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Philogen S.p.A. (1) · Shang Panfeng (1) · Sun Yat-sen University (1) · The Affiliated Hospital of Qingdao University (1)
United States (9) · China (4) · Italy (4) · France (3) · Germany (3) · Spain (3) · Belgium (2) · Australia (1) · Austria (1) · Israel (1) · Netherlands (1) · New Zealand (1) · Poland (1) · Switzerland (1) · United Kingdom (1)
Brian Rini, MD (1) · Li Huo, MD (1) · Sam Whiting, MD, PhD (1) · Shadi Abdar Esfahani, MD, MPH (1)
PMID 16880406, PMID 16885386, PMID 29224225, PMID 30931980, PMID 37011650, PMID 39462179, PMID 39756444, PMID 41857358
2023 (1), 2025 (1)